United Health Products Enlists NAMSA to Lead Pivotal Clinical Study for FDA Approval

summarizeSummary

United Health Products announced an agreement with NAMSA to sponsor a new clinical study of its CelluSTAT hemostatic gauze, a key step toward FDA approval and resolution of an outstanding Warning Letter.

check_boxKey Events · Product Development and Regulatory · UEEC

• NAMSA to Sponsor Pivotal Study

  NAMSA, a global MedTech CRO, will serve as regulatory sponsor for a new clinical study of CelluSTAT Hemostatic Gauze, with UHP holding exclusive data rights for a revised PMA application.

• IDE Submission Planned

  NAMSA will initially seek an Investigational Device Exemption (IDE) from the FDA to organize and conduct the study, a prerequisite for human trials.

• Warning Letter Resolution Path

  The study will proceed in parallel with UHP's efforts to resolve the outstanding FDA Warning Letter, a critical regulatory overhang.

• FDA Alignment Confirmed

  The plan aligns with the FDA's March 2026 approval of UHP's proposal to have a non-affiliated party oversee the clinical study.

auto_awesomeAnalysis · UEEC · Industrial Applications And Services

United Health Products, a zero-revenue company operating under a going-concern warning, has secured NAMSA—a respected MedTech CRO—to sponsor a new clinical study of its CelluSTAT hemostatic gauze. This marks a concrete step toward resolving the FDA's outstanding Warning Letter and resubmitting a Premarket Approval application. The agreement follows the FDA's March approval of the company's proposal to have a non-affiliated party oversee the study, and it provides a path to generate the human data needed for market access. While the study still requires an IDE and successful execution, the partnership with an experienced CRO reduces regulatory risk and extends the company's survival narrative.